Quantbot Technologies LP Sells 30,286 Shares of Humana Inc. (NYSE:HUM)

Quantbot Technologies LP decreased its holdings in shares of Humana Inc. (NYSE:HUM - Free Report) by 95.9% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 1,298 shares of the insurance provider's stock after selling 30,286 shares during the period. Quantbot Technologies LP's holdings in Humana were worth $329,000 as of its most recent SEC filing.

A number of other large investors have also recently made changes to their positions in the business. State Street Corp lifted its position in Humana by 1.0% in the 3rd quarter. State Street Corp now owns 5,357,420 shares of the insurance provider's stock valued at $1,701,582,000 after acquiring an additional 53,272 shares in the last quarter. Pzena Investment Management LLC lifted its stake in Humana by 44.0% during the 4th quarter. Pzena Investment Management LLC now owns 3,609,382 shares of the insurance provider's stock valued at $915,736,000 after acquiring an additional 1,103,132 shares in the last quarter. Boston Partners grew its stake in shares of Humana by 435.8% in the 4th quarter. Boston Partners now owns 1,098,702 shares of the insurance provider's stock worth $279,236,000 after acquiring an additional 893,637 shares in the last quarter. Two Sigma Advisers LP raised its holdings in shares of Humana by 2.4% in the third quarter. Two Sigma Advisers LP now owns 1,043,580 shares of the insurance provider's stock valued at $330,544,000 after purchasing an additional 24,500 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. lifted its position in shares of Humana by 7.3% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 964,926 shares of the insurance provider's stock valued at $244,811,000 after purchasing an additional 65,735 shares in the last quarter. 92.38% of the stock is owned by institutional investors.

Remove Ads

Humana Price Performance

NYSE:HUM traded up $0.26 during trading hours on Tuesday, hitting $264.86. 373,973 shares of the company's stock traded hands, compared to its average volume of 1,751,243. The firm has a market cap of $31.97 billion, a P/E ratio of 26.71, a P/E/G ratio of 2.05 and a beta of 0.57. The company has a quick ratio of 1.76, a current ratio of 1.76 and a debt-to-equity ratio of 0.68. The business's fifty day simple moving average is $269.77 and its two-hundred day simple moving average is $273.07. Humana Inc. has a 52 week low of $213.31 and a 52 week high of $406.46.

Humana (NYSE:HUM - Get Free Report) last posted its quarterly earnings data on Tuesday, February 11th. The insurance provider reported ($2.16) earnings per share for the quarter, topping the consensus estimate of ($2.26) by $0.10. Humana had a net margin of 1.02% and a return on equity of 11.70%. On average, research analysts anticipate that Humana Inc. will post 16.47 earnings per share for the current fiscal year.

Humana Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, April 25th. Shareholders of record on Friday, March 28th will be given a dividend of $0.885 per share. The ex-dividend date of this dividend is Friday, March 28th. This represents a $3.54 dividend on an annualized basis and a yield of 1.34%. Humana's payout ratio is 35.58%.

Analyst Upgrades and Downgrades

Several equities research analysts have commented on the stock. Piper Sandler increased their price objective on shares of Humana from $270.00 to $288.00 and gave the company a "neutral" rating in a research note on Wednesday, January 15th. StockNews.com downgraded Humana from a "buy" rating to a "hold" rating in a research report on Tuesday, March 18th. Barclays upped their price objective on Humana from $255.00 to $270.00 and gave the company an "equal weight" rating in a research note on Thursday, February 13th. Truist Financial lifted their target price on Humana from $260.00 to $290.00 and gave the stock a "hold" rating in a research note on Monday, January 6th. Finally, Morgan Stanley reduced their price target on shares of Humana from $301.00 to $285.00 and set an "equal weight" rating for the company in a research report on Wednesday, February 12th. Eighteen investment analysts have rated the stock with a hold rating and five have issued a buy rating to the company. Based on data from MarketBeat, the stock presently has an average rating of "Hold" and a consensus target price of $285.68.

Humana Company Profile

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.